No. As of September 2026, Aclaris Therapeutics, Inc. (ACRS) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.00% / 30% · (Cash+Inv) / Mkt Cap (36m) 29.8% / 30% · Interest income / Revenue 124.8% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 0.00% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 16.6% / 33% · Receivables / Mkt Cap (36m) 1.30% / 49% · Interest income / Revenue 124.8% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 0.00% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 16.6% / 33.33% · Receivables / Mkt Cap (24m) 1.30% / 33.33% · Interest income / Revenue 124.8% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 0.15% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 53.2% / 33.33% · Receivables / Avg Assets (4Q) 3.38% / 33.33% · Interest income / Revenue 124.8% / 5% | Fail |
| FTSE | Debt / Total Assets 0.00% / 33.33% · (Cash+ST Inv) / Total Assets 52.9% / 33.33% · (Cash+Recv) / Total Assets 57.0% / 33.33% · Interest income / Revenue 124.8% / 5% | Fail |
No. As of September 2026, Aclaris Therapeutics, Inc. (ACRS) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. Aclaris Therapeutics, Inc. is over the AAOIFI limit on Interest income / Revenue.
About 124.8% of each dividend: Aclaris Therapeutics, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.
Aclaris Therapeutics, Inc. (NASDAQ: ACRS) is a Healthcare company (Biotechnology) with a market capitalization of $536M. The Maz Rating grades it against the other companies in its sector.
Aclaris Therapeutics, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $3.38, Aclaris Therapeutics, Inc. trades at 82.6x sales and 3.0x book value. Over the last twelve months it generated about $6M of revenue and a net loss of $93M. It runs a gross margin of 99.8%, an operating margin of -1414.0% and a net margin of -1244.1%. It shows return on equity of -59.2%, return on invested capital of -47.2% and a free cash flow yield of -14.1%. On the balance sheet: a debt-to-equity ratio of 0.00 and a current ratio of 5.09. Over the past 52 weeks the share price ranged from $2.34 to $6.60, with a beta of 0.80.
Aclaris Therapeutics, Inc. does not currently pay a dividend.
17 Wall Street analyst ratings cover the stock: 14 Buy and 3 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Aclaris Therapeutics, Inc., a biopharmaceutical firm operating in the United States, is currently in the clinical development phase, focused on creating novel therapeutic agents for various immune-inflammatory conditions. The company's operations are divided into two primary divisions: the Therapeutics segment, dedicated to discovering and progressing innovative treatments to address crucial unmet needs in immuno-inflammatory disorders; and the Contract Research segment, which delivers specialized laboratory services. The company's pipeline features several investigational compounds. Among these is Zunsemetinib, an MK2 inhibitor, being developed to treat moderate to severe cases of rheumatoid arthritis, psoriatic arthritis, and hidradenitis suppurativa. Another significant candidate is ATI-1777, a soft JAK 1/3 inhibitor, intended for the management of moderate to severe atopic dermatitis. Additionally, Aclaris is advancing ATI-2138, an ITK/TXK/JAK3 inhibitor, as a potential intervention for T cell-mediated autoimmune diseases; a Gut-Biased Program targeting inflammatory bowel disease; and ATI-2231, an MK2 inhibitor, for the treatment of pancreatic and metastatic breast cancer. Established in 2012, Aclaris Therapeutics, Inc. has its corporate headquarters situated in Wayne, Pennsylvania.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.